MX2010006182A - Derivados de isoxazolo-piridazina. - Google Patents

Derivados de isoxazolo-piridazina.

Info

Publication number
MX2010006182A
MX2010006182A MX2010006182A MX2010006182A MX2010006182A MX 2010006182 A MX2010006182 A MX 2010006182A MX 2010006182 A MX2010006182 A MX 2010006182A MX 2010006182 A MX2010006182 A MX 2010006182A MX 2010006182 A MX2010006182 A MX 2010006182A
Authority
MX
Mexico
Prior art keywords
sup
optionally substituted
halo
membered
isoxazolo
Prior art date
Application number
MX2010006182A
Other languages
English (en)
Inventor
Bernd Buettelmann
Roland Jakob-Roetne
Andrew Thomas
Hanner Knust
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010006182A publication Critical patent/MX2010006182A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I (ver fórmula (I)) en la que X es O o NH; R1 es fenilo, piridinilo, o pirimidinilo, cada uno de ellos está opcionalmente sustituido por uno, dos o tres halógenos, R2 es alquilo C1-4, H o haloalquilo C1-4; R3, R4 y R5 con independencia entre sí son: H, alquilo C1-7, opcionalmente sustituido por uno o más halógeno, ciano o hidroxi, alcoxi C1-7, opcionalmente sustituido por uno o más halógenos, CN, halógeno, NO2, -C(O)-Ra, en el que Ra es hidroxi, alcoxi C1-7, alquilo C1-7, fenoxi o fenilo, -NRbRc, en el que Rb y Rc con independencia entre sí son: hidrógeno, alquilo C1-7, -C(O)-alquilo C1-7, opcionalmente sustituido por uno o más halógenos, -C(O) (CH2)m-O-alquilo C1-7, en el que m es el número 0, 1, 2, 3, 4, 5 ó 6, -C(O)C(O)O-alquilo C1-7, -C(O)CH2C(O)O-alquilo C1-7, -C(O)Ri, dicho Ri es fenilo o heteroarilo de 5 ó 6 miembros, cada uno de ellos está opcionalmente sustituido por uno o más E, -C(O)-cicloalquilo C3-7, opcionalmente sustituido por uno o más B, -C(O)-Rii, dicho Rii es heterociclilo de 3 a 7 miembros, opcionalmente sustituido por uno o más A, heterociclilo de 3 a 7 miembros, opcionalmente sustituido por uno o más A, heteroarilo de 5 ó 6 miembros, opcionalmente sustituido por uno o más E, C(O)NRdRe, en el que Rd y Re con independencia entre sí son: H, alquilo C1-7, opcionalmente sustituido por uno o más halógeno, hidroxi, o ciano, -(CH2)-cicloalquilo C3-7, opcionalmente sustituido por uno o más B y t es el número 0, 1, 2, 3 ó 4, -(CH2)u-O-alquilo C1-7, en el que u es el número 2, 3, 4, 5 ó 6, -(CH2)x-heterociclilo, en el que x es el número 0, 1, 2, 3 ó 4, y dicho heterociclilo está opcionalmente sustituido por uno o más A, Rd y Re junto con el nitrógeno al que están unidos forman un resto heterociclilo opcionalmente sustituido por uno o más A, o R3 junto con el átomo de nitrógeno contiguo de la piridazina forma un anillo aromático fusionado de 5 miembros con otros dos átomos de nitrógeno del anillo, el anillo fusionado está opcionalmente sustituido por Rf, dicho Rf es alquilo C1-7, -C(O)O-alquilo C1-7, -C(O)-alquilo C1-7, heteroarilo de 5 ó 6 miembros o fenilo, cada uno de ellos está opcionalmente sustituido por uno o más E, A es hidroxi, oxo, alquilo C1-7, alcoxi C1-7, haloalquilo C1-7, hidroxialquilo C1-7, halógeno o CN, B es halógeno, hidroxi, CN, alquilo C1-4 o haloalquilo C1-4, E es halógeno, CN, NO2, hidroxi, alquilo C1-7, alcoxi C1-7, haloalquilo C1-7, hidroxialquilo C1-7, ciano-alquilo C1-7, haloalcoxi C1-7 o cicloalquilo C3-7, o una sal farmacéuticamente aceptable de los mismos, que tienen afinidad y selectividad para con el sitio de fijación del receptor de GABA A a5, a su obtención, a composiciones farmacéuticas que los contienen y al uso de los mismos como medicamentos. Los compuestos activos de la presente invención son útiles como mejoradores cognitivos o para el tratamiento de trastornos cognitivos, por ejemplo la enfermedad de Alzheimer.
MX2010006182A 2007-12-04 2008-11-26 Derivados de isoxazolo-piridazina. MX2010006182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122293 2007-12-04
PCT/EP2008/066226 WO2009071477A1 (en) 2007-12-04 2008-11-26 Isoxazolo-pyridazine derivatives

Publications (1)

Publication Number Publication Date
MX2010006182A true MX2010006182A (es) 2010-07-01

Family

ID=40328910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006182A MX2010006182A (es) 2007-12-04 2008-11-26 Derivados de isoxazolo-piridazina.

Country Status (15)

Country Link
US (1) US7943619B2 (es)
EP (1) EP2231651B1 (es)
JP (1) JP5301558B2 (es)
KR (1) KR101175855B1 (es)
CN (1) CN101868458B (es)
AR (1) AR069525A1 (es)
AU (1) AU2008333327B2 (es)
BR (1) BRPI0820113A2 (es)
CA (1) CA2707821C (es)
CL (1) CL2008003593A1 (es)
IL (1) IL205753A0 (es)
MX (1) MX2010006182A (es)
PE (1) PE20091446A1 (es)
TW (1) TW200924775A (es)
WO (1) WO2009071477A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2767536T3 (pl) 2007-12-04 2016-01-29 Hoffmann La Roche Pochodne izoksazolo-pirydyny
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス, インコーポレイテッド アリールgpr120受容体アゴニストおよびその使用
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
CA2759598C (en) * 2009-05-05 2017-09-12 F. Hoffmann-La Roche Ag Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
BRPI1013844A2 (pt) * 2009-05-05 2016-04-12 Hoffmann La Roche derivados de piridina-isoxazol
CA2760746C (en) * 2009-05-05 2017-07-11 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
CA2760597C (en) * 2009-05-05 2017-08-22 F. Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2638035B1 (en) * 2010-11-09 2014-12-17 F.Hoffmann-La Roche Ag Triazole derivatives as ligands for Gaba receptors
MX346185B (es) * 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
WO2013045519A1 (en) 2011-09-27 2013-04-04 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US9273011B2 (en) * 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001281A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN107344939A (zh) * 2016-05-06 2017-11-14 如东赛默罗生物科技有限公司 咪唑[2,1-a]酞嗪类衍生物、其制备方法、药物组合物和用途
JP7084405B2 (ja) * 2016-12-08 2022-06-14 エフ.ホフマン-ラ ロシュ アーゲー Gaba a alpha5 pamとしての新規イソキサゾリルエーテル誘導体
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019238633A1 (en) 2018-06-13 2019-12-19 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
CN112979655A (zh) * 2019-12-16 2021-06-18 上海赛默罗生物科技有限公司 ***并哒嗪类衍生物、其制备方法、药物组合物和用途
US20240043418A1 (en) 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
WO2022234271A1 (en) 2021-05-05 2022-11-10 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
WO2024088928A1 (en) * 2022-10-25 2024-05-02 F. Hoffmann-La Roche Ag Process for manufacturing alogabat

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) * 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
US6297235B1 (en) * 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
WO2001034603A2 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
WO2003004027A1 (en) 2001-07-05 2003-01-16 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
EP1448561B1 (en) 2001-11-20 2008-02-20 Eli Lilly And Company Beta 3 adrenergic agonists
GB0128160D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
RU2408589C2 (ru) * 2004-05-14 2011-01-10 Айрм Ллк Соединения и композиции в качестве модуляторов ppar-рецепторов, активируемых пролифератором пероксисом
DE602005007350D1 (de) 2004-06-01 2008-07-17 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
MX2007003648A (es) * 2004-10-01 2007-06-11 Hoffmann La Roche Derivados de eter sustituido con hexafluoroisopropanol.
EP1812427A4 (en) 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
JPWO2006095882A1 (ja) 2005-03-07 2008-08-21 パイオニア株式会社 ホログラム装置及び記録方法
WO2006095822A1 (ja) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. スルホンアミド化合物およびその医薬
EP1899299B1 (en) * 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE502006008095D1 (de) 2005-07-20 2010-11-25 Prospective Concepts Ag Pneumatisch verstellbare seitenwangen für fahrzeugsitze
CA2623043A1 (en) 2005-09-19 2007-04-12 F. Hoffman-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008130951A1 (en) * 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors

Also Published As

Publication number Publication date
AU2008333327B2 (en) 2012-12-06
AU2008333327A1 (en) 2009-06-11
BRPI0820113A2 (pt) 2015-05-05
CA2707821C (en) 2016-06-07
PE20091446A1 (es) 2009-09-24
KR20100074320A (ko) 2010-07-01
JP2011505402A (ja) 2011-02-24
KR101175855B1 (ko) 2012-08-24
CN101868458A (zh) 2010-10-20
US7943619B2 (en) 2011-05-17
US20090143385A1 (en) 2009-06-04
EP2231651B1 (en) 2018-11-21
JP5301558B2 (ja) 2013-09-25
CL2008003593A1 (es) 2010-01-04
EP2231651A1 (en) 2010-09-29
AR069525A1 (es) 2010-01-27
IL205753A0 (en) 2010-11-30
TW200924775A (en) 2009-06-16
CA2707821A1 (en) 2009-06-11
WO2009071477A1 (en) 2009-06-11
CN101868458B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
MX2010006182A (es) Derivados de isoxazolo-piridazina.
MX2010005753A (es) Derivados de isoxazolo-pirazina.
IL278297B1 (en) Transmutable heterocyclic ptpn11 inhibitors
GEP201706611B (en) Amido compounds and their use as pharmaceuticals
TW200607807A (en) Macrocyclic beta-secretase inhibitors
WO2007110627A3 (en) 3,7-diamino-10h-phenothiazine salts and their use
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2006024486A3 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
RS107504A (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use
RU2013138717A (ru) Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
TW200621249A (en) Substituted amide beta secretase inhibitors
UA100132C2 (en) Isoxazolo-pyridine derivatives
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
MY139446A (en) Novel quinoline derivatives
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
WO2006053039A3 (en) Hydroxybenzoate salts of metanicotine compounds
MX2009014001A (es) Derivados de isoxazol-imidazol.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain

Legal Events

Date Code Title Description
FG Grant or registration